Skip to main content
TipRanks
Go Ultimate75% OFF

SELLAS Life Sciences Group (RXK3) Stock Statistics & Valuation Metrics

2 Followers

Total Valuation

SELLAS Life Sciences Group has a market cap or net worth of EUR 2.76B. The enterprise value is EUR 2.36B.

Market Cap
EUR 2.76B
Enterprise Value
EUR 2.36B

Share Statistics

SELLAS Life Sciences Group has 203,859,150 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
203,859,150
Owned by Insiders
1.63%
Owned by Institutions
39.59%

Financial Efficiency

SELLAS Life Sciences Group’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -39.34%.

Return on Equity (ROE)
-0.38
Return on Assets (ROA)
-0.34
Return on Invested Capital (ROIC)
-39.34%
Return on Capital Employed (ROCE)
-0.40
Revenue Per Employee
0
Profits Per Employee
-2.07M
Employee Count
13
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of SELLAS Life Sciences Group is -68.75. SELLAS Life Sciences Group’s PEG ratio is -1.72.

PE Ratio
-68.75
PS Ratio
0.00
PB Ratio
20.98
Price to FCF
-102.02
Price to Operating Cash Flow
-101.31
PEG Ratio
-1.72

Income Statement

In the last 12 months, SELLAS Life Sciences Group had revenue of 0 and earned -26.86M in profits. Earnings per share was -0.25.

Revenue
0
Gross Profit
0
Operating Income
-28.27M
Pretax Income
-26.86M
Net Income
-26.86M
EBITDA
-26.86M
Earnings Per Share (EPS)
-0.25

Cash Flow

In the last 12 months, operating cash flow was -27.30M and capital expenditures 0, giving a free cash flow of -27.30M billion.

Operating Cash Flow
-27.30M
Free Cash Flow
-27.30M
Free Cash Flow per Share
-0.13

Dividends & Yields

SELLAS Life Sciences Group pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-0.98%
Earnings Yield
-1.29%

Stock Price Statistics

Beta
-0.46
52-Week Price Change
824.15%
50-Day Moving Average
9.97
200-Day Moving Average
7.94
Relative Strength Index (RSI)
57.95
Average Volume (3m)
1,444

Important Dates

SELLAS Life Sciences Group upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 12, 2026
Next Earnings Date
Mar 25, 2027
Ex-Dividend Date
―

Financial Position

SELLAS Life Sciences Group as a current ratio of 10.72, with Debt / Equity ratio of 1.41%

Current Ratio
10.72
Quick Ratio
10.72
Debt to Market Cap
0.00
Net Debt to EBITDA
2.64
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, SELLAS Life Sciences Group has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

SELLAS Life Sciences Group EV to EBITDA ratio is -74.06, with an EV/FCF ratio of -97.03.

EV to Sales
0.00
EV to EBITDA
-74.06
EV to Free Cash Flow
-97.03
EV to Operating Cash Flow
-97.03

Balance Sheet

SELLAS Life Sciences Group has EUR 134.71M in cash and marketable securities with EUR 599.00K in debt, giving a net cash position of EUR 134.11M billion.

Cash & Marketable Securities
EUR 134.71M
Total Debt
EUR 599.00K
Net Cash
EUR 134.11M
Net Cash Per Share
EUR 0.66
Tangible Book Value Per Share
EUR 0.64

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for SELLAS Life Sciences Group is EUR 36.48, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
EUR 36.48
Price Target Upside
190.67% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
―
EPS Growth Forecast
34.25%

Scores

Smart Score
5
AI Score
―